Nyxoah Strengthens Leadership with New CFO Appointment
Nyxoah SA, a leading medical technology company, has recently made a significant addition to its leadership team by appointing John Landry as the new Chief Financial Officer (CFO). This strategic move, which is particularly timely due to the ongoing expansion into the U.S. market, marks a pivotal shift in Nyxoah's executive roster.
Background of John Landry's Financial Leadership
John Landry brings a wealth of experience to his new role, particularly in financial leadership within the healthcare and medtech industries. Over the past two decades, he has honed his skills and developed a proven track record in driving growth and achieving operational efficiencies, not only in public companies but also in private enterprises. His recent position as CFO at Vapotherm Inc. allowed him to implement financial strategies that significantly advanced the company’s market share and revenue growth in the U.S.
Company's Enhanced Focus on U.S. Market
As Nyxoah continues to expand its footprint, the integration of Landry into the leadership team is seen as an essential strategy. Olivier Taelman, CEO of Nyxoah, expressed his enthusiasm for Landry's appointment, emphasizing how his extensive knowledge of the U.S. healthcare landscape and investor relations will greatly benefit the company’s growth initiatives. This leadership change aligns with Nyxoah's aim to optimize financial strategies while preparing for the U.S. commercialization of their innovative Genio system.
Transition of Previous CFO to President International
In conjunction with Landry's appointment, Loïc Moreau, the outgoing CFO, will transition into a newly established position as President International. In this role, Moreau will spearhead Nyxoah's efforts to enhance its global presence, reinforcing the company’s ambitions to solidify its standing in key international markets.
Innovative Solutions for Obstructive Sleep Apnea
Nyxoah's commitment to advancing treatment for Obstructive Sleep Apnea (OSA) is foundational to its operations. The company's flagship innovation, Genio, represents a groundbreaking treatment via hypoglossal neuromodulation. Unlike existing therapies, this battery-free device is placed through a single incision under the chin and operates with a wearable controller. Nyxoah’s passion for innovation is complemented by its commitment to clinical evidence, which has consistently resulted in remarkable outcomes for patients suffering from OSA.
Achievements and Regulatory Approvals
Since Nyxoah's inception, the company has achieved significant milestones, including receiving the European CE Mark for the Genio system following the successful BLAST OSA study. Additionally, Nyxoah's accomplishments have seen it conduct two successful IPOs, with listings on Euronext Brussels and NASDAQ. Most recently, positive results from the BETTER SLEEP study have led to an expansion of therapeutic indications for Genio, specifically targeting Complete Concentric Collapse (CCC) patients.
Commitment to Future Growth
Nyxoah’s strategic appointments reflect its dedication to building a robust, diversified leadership team to drive its ambitious growth pursuits. As the company positions itself for expansion into the U.S. market, the synergy between the new CFO and the outgoing CFO's transition aims to create a solid framework for Nyxoah’s future achievements.
Frequently Asked Questions
Who is the new CFO of Nyxoah?
John Landry has been appointed as the new CFO of Nyxoah, effective immediately.
What will Loïc Moreau's new role be?
Loïc Moreau will transition to the position of President International at Nyxoah, focusing on global expansion efforts.
What is Genio?
Genio is Nyxoah’s innovative treatment solution for Obstructive Sleep Apnea, utilizing hypoglossal neuromodulation.
What are Nyxoah's future growth plans?
Nyxoah aims to accelerate its growth in the U.S. market while enhancing its presence in key international markets.
Where can I learn more about Nyxoah's products?
Information about Nyxoah's offerings can be found on their official website and through their investor relations.
